Case Report
Copyright ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Aug 6, 2023; 11(22): 5351-5357
Published online Aug 6, 2023. doi: 10.12998/wjcc.v11.i22.5351
Treatment of refractory anti-melanoma differentiation-associated gene 5 anbibody-positive dermatomyositis complicated by rapidly progressing interstitial pulmonary disease: Two case reports
Qiao-Hong Wang, Li-Heng Chen
Qiao-Hong Wang, Department of Rheumatology, Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310009, Zhejiang Province, China
Li-Heng Chen, Department of Endocrinology, Fourth Affiliated Hospital, College of Medicine, Zhejiang University, Yiwu 322000, Zhejiang Province, China
Author contributions: Wang QH was involved in conceptualization, supervision, and manuscript writing; Chen LH was involved in manuscript writing.
Informed consent statement: Informed consent was obtained from the patients for the publication of this case report.
Conflict-of-interest statement: The authors declare that they have no conflicting interest to disclose.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Qiao-Hong Wang, MS, Associate Chief Physician, Department of Rheumatology, Second Affiliated Hospital, College of Medicine, Zhejiang University, No. 88 Jiefang Road, Hangzhou 310009, Zhejiang Province, China. 2202015@zju.edu.cn
Received: April 5, 2023
Peer-review started: April 5, 2023
First decision: May 19, 2023
Revised: May 30, 2023
Accepted: July 4, 2023
Article in press: July 4, 2023
Published online: August 6, 2023
Core Tip

Core Tip: The early detection of myositis-related antibody profile and its concentration together with serum ferritin and cytokine levels is key to the clinical diagnosis and prognosis of anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis complicated with rapidly progressive interstitial lung disease (anti-MDA5 Ab+ DM-RP-ILD). For patients with anti-MDA5 Ab+ DM-RP-ILD refractory to intensive immunosuppression, tocilizumab could be a salvage treatment.